DNL201
DNLI-B-0002
Phase 1 small_molecule completed
Quick answer
DNL201 for Parkinson Disease is a Phase 1 program (small_molecule) at Denali Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Denali Therapeutics
- Indication
- Parkinson Disease
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed